|
|
https://mb.cision.com/Public/18595/3782037/8d068772533d2f55_800x800ar.png
UCB Receives New European Commission Approvals for BIMZELX^=C2=AE=E2=96=
=BCbimekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyl=
oarthritis
=C2=B7 Bimekizumab is the first and only IL17A and IL17F inhibitor approv=
ed in the European Union for active psoriatic arthritis PsA and active ax=
ial... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3777400/84a390fae205c254_800x800ar.png
New LongTerm Data on Bimekizumab in Psoriatic Arthritis and Axial Spond=
yloarthritis Presented at EULAR 2023
=C2=B7 In patients with psoriatic arthritis with prior inadequate response =
to tumour necrosis factor inhibitors, bimekizumab demonstrated sustained jo=
int and skin clearance responses to week... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3775463/9d8e27cb55c96e14_800x800ar.png
UCB Showcases Commitment to Advancing Care in ImmuneMediated Inflammato=
ry Diseases with 23 Abstracts at EULAR 2023
=C2=B7 Data to be presented on bimekizumab, CIMZIA^=C2=AE certolizumab peg=
ol, and dapirolizumab pegol
=C2=B7 First presentation of bimekizumab 52week data from the openlabel e=
xtension of the... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3775771/ad3c6efe37399dd8_800x800ar.png
Transparency notification FMR LLC
Brussels Belgium, 26 May 2023 =E2=80=93 20:00 CEST =E2=80=93 Regulated =
information=C2=A0
1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large =
shareholdings, UCB SA/NV announces that it received a transparency... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3772832/988681b1eeadff20_800x800ar.png
UCB and Veeva collaborate to advance the patient experience in clinical =
trials
=C2=B7 Companies to work together to set a new standard for patient centric=
digital clinical trials
Brussels Belgium, and Pleasanton, CA US, 23 May 2023 07:00 CET UCB,=
a global biopharmaceutical company, and Veeva Systems... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3760702/986c42489e4f9676_800x800ar.png
UCB and Ariceum Therapeutics sign a Strategic Research Collaboration to =
Discover New Modalities for the Treatment of Immunerelated Diseases and Ca=
ncer
=C2=B7 UCB=E2=80=99s expertise in macrocyclic peptide discovery, using its =
proprietary mRNAdisplay platform, ExtremeDiversity=E2=84=A2, will aid... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3760134/903d0b2944774e2b_800x800ar.png
UCB=E2=80=99s General Meeting of Shareholders 2023
=C2=B7 For financial year 2022: Gross dividend of =E2=82=AC 1.33 per share =
2%, payable 03 May 2023
=C2=B7 All agenda items put to vote approved
=C2=B7 The message of JeanChristophe Tellier, CEO of UCB is available on U=
CB=E2=80=99s global corporate... Lire le communiqué |
|
| |
|
| |
